-
Study aim
-
he evaluation of the safety and efficiency of the chitosan hydrogel system and the investigation of the synergistic effect of the optimized concentrations of antibiotics in preventing the progress of infection and healing the tissue of burn wounds is in phase one of the Clinical Trial.
-
Design
-
Clinical trial with control group, with parallel groups, double blind, non- random, phase 1 on 50 patients.
-
Settings and conduct
-
Infectious second degree burn patients are selected from those who refer to Zare Hospital. In this way, all the patients who enter, provided they meet the entry criteria and do not have the exit criteria and complete the consent form until the required number of the study is filled, are accepted and entered the study without exception.
-
Participants/Inclusion and exclusion criteria
-
Patients with 2nd degree burns whose wounds have secretory exudate.
The size of the wound is greater than or equal to 10 cm.
The location and shape of the wound can be divided into two separate areas.
No more than a week has passed since the patients were hospitalized.
-
Intervention groups
-
Group A: Wound covered with antibacterial chitosan hydrogel dressing.
Group B: wound covered with sulfadiazine antibacterial dressing.
In each of the patients, the wounds are treated simultaneously in 2 methods A and B (Within-person RCT), in such a way that depending on the extent of the wound, the wound is divided into two equal parts, left and right or upper and lower.
-
Main outcome variables
-
Wounds are evaluated during the 21-day treatment period. On day zero, biopsy and exudate are taken from the wound and bacterial culture is performed. Then every 6 days, exudate samples are taken from the wound and bacterial culture is done to record the bacteria count by colony counting method. Wounds are photographed every 3 days and redness, inflammation and pain are recorded according to the checklist.